nodes	percent_of_prediction	percent_of_DWPC	metapath
Methylnaltrexone—Stinging—Calcium Acetate—osteoporosis	0.0438	0.0438	CcSEcCtD
Methylnaltrexone—Redness—Ibandronate—osteoporosis	0.0286	0.0287	CcSEcCtD
Methylnaltrexone—Redness—Calcitriol—osteoporosis	0.028	0.028	CcSEcCtD
Methylnaltrexone—Redness—Pamidronate—osteoporosis	0.0224	0.0224	CcSEcCtD
Methylnaltrexone—Redness—Zoledronate—osteoporosis	0.0205	0.0205	CcSEcCtD
Methylnaltrexone—Injection site reaction—Ibandronate—osteoporosis	0.0192	0.0192	CcSEcCtD
Methylnaltrexone—Redness—Estradiol—osteoporosis	0.0158	0.0158	CcSEcCtD
Methylnaltrexone—Injection site reaction—Zoledronate—osteoporosis	0.0137	0.0138	CcSEcCtD
Methylnaltrexone—Oedema—Calcium Acetate—osteoporosis	0.0127	0.0127	CcSEcCtD
Methylnaltrexone—Pain—Calcium Acetate—osteoporosis	0.0108	0.0108	CcSEcCtD
Methylnaltrexone—Erythema—Etidronic acid—osteoporosis	0.0102	0.0102	CcSEcCtD
Methylnaltrexone—Flatulence—Etidronic acid—osteoporosis	0.01	0.01	CcSEcCtD
Methylnaltrexone—Pain—Ergocalciferol—osteoporosis	0.00956	0.00957	CcSEcCtD
Methylnaltrexone—Erythema—Estropipate—osteoporosis	0.0088	0.00882	CcSEcCtD
Methylnaltrexone—Flatulence—Estropipate—osteoporosis	0.00868	0.00869	CcSEcCtD
Methylnaltrexone—Erythema—Alendronate—osteoporosis	0.00867	0.00868	CcSEcCtD
Methylnaltrexone—Diarrhoea—Calcium Acetate—osteoporosis	0.00866	0.00867	CcSEcCtD
Methylnaltrexone—Flatulence—Alendronate—osteoporosis	0.00854	0.00856	CcSEcCtD
Methylnaltrexone—Erythema—Ibandronate—osteoporosis	0.00844	0.00846	CcSEcCtD
Methylnaltrexone—Flatulence—Raloxifene—osteoporosis	0.0084	0.00842	CcSEcCtD
Methylnaltrexone—Dizziness—Calcium Acetate—osteoporosis	0.00837	0.00838	CcSEcCtD
Methylnaltrexone—Flatulence—Ibandronate—osteoporosis	0.00832	0.00833	CcSEcCtD
Methylnaltrexone—Erythema—Calcitriol—osteoporosis	0.00826	0.00828	CcSEcCtD
Methylnaltrexone—Vomiting—Calcium Acetate—osteoporosis	0.00804	0.00806	CcSEcCtD
Methylnaltrexone—Nausea—Calcium Acetate—osteoporosis	0.00751	0.00753	CcSEcCtD
Methylnaltrexone—Unspecified disorder of skin and subcutaneous tissue—Estropipate—osteoporosis	0.00744	0.00746	CcSEcCtD
Methylnaltrexone—Unspecified disorder of skin and subcutaneous tissue—Raloxifene—osteoporosis	0.00721	0.00722	CcSEcCtD
Methylnaltrexone—Oedema—Estropipate—osteoporosis	0.00719	0.0072	CcSEcCtD
Methylnaltrexone—Unspecified disorder of skin and subcutaneous tissue—Ibandronate—osteoporosis	0.00714	0.00715	CcSEcCtD
Methylnaltrexone—Nervous system disorder—Estropipate—osteoporosis	0.00705	0.00706	CcSEcCtD
Methylnaltrexone—Skin disorder—Estropipate—osteoporosis	0.00698	0.00699	CcSEcCtD
Methylnaltrexone—Flatulence—Risedronate—osteoporosis	0.00686	0.00687	CcSEcCtD
Methylnaltrexone—Nervous system disorder—Raloxifene—osteoporosis	0.00683	0.00684	CcSEcCtD
Methylnaltrexone—Gastrointestinal pain—Etidronic acid—osteoporosis	0.00679	0.0068	CcSEcCtD
Methylnaltrexone—Skin disorder—Raloxifene—osteoporosis	0.00676	0.00677	CcSEcCtD
Methylnaltrexone—Nervous system disorder—Ibandronate—osteoporosis	0.00676	0.00677	CcSEcCtD
Methylnaltrexone—Hyperhidrosis—Raloxifene—osteoporosis	0.00673	0.00674	CcSEcCtD
Methylnaltrexone—Skin disorder—Ibandronate—osteoporosis	0.00669	0.0067	CcSEcCtD
Methylnaltrexone—Hyperhidrosis—Ibandronate—osteoporosis	0.00666	0.00667	CcSEcCtD
Methylnaltrexone—Nausea—Ergocalciferol—osteoporosis	0.00664	0.00665	CcSEcCtD
Methylnaltrexone—Erythema—Pamidronate—osteoporosis	0.00661	0.00662	CcSEcCtD
Methylnaltrexone—Abdominal pain—Etidronic acid—osteoporosis	0.00657	0.00658	CcSEcCtD
Methylnaltrexone—Skin disorder—Calcitriol—osteoporosis	0.00655	0.00656	CcSEcCtD
Methylnaltrexone—Gastrointestinal disorder—Estropipate—osteoporosis	0.0062	0.00621	CcSEcCtD
Methylnaltrexone—Pain—Estropipate—osteoporosis	0.00614	0.00615	CcSEcCtD
Methylnaltrexone—Pain—Alendronate—osteoporosis	0.00605	0.00606	CcSEcCtD
Methylnaltrexone—Erythema—Zoledronate—osteoporosis	0.00604	0.00605	CcSEcCtD
Methylnaltrexone—Unspecified disorder of skin and subcutaneous tissue—Ethinyl Estradiol—osteoporosis	0.00603	0.00604	CcSEcCtD
Methylnaltrexone—Gastrointestinal disorder—Raloxifene—osteoporosis	0.00601	0.00602	CcSEcCtD
Methylnaltrexone—Pain—Raloxifene—osteoporosis	0.00595	0.00596	CcSEcCtD
Methylnaltrexone—Gastrointestinal disorder—Ibandronate—osteoporosis	0.00595	0.00596	CcSEcCtD
Methylnaltrexone—Pain—Ibandronate—osteoporosis	0.00589	0.0059	CcSEcCtD
Methylnaltrexone—Unspecified disorder of skin and subcutaneous tissue—Risedronate—osteoporosis	0.00588	0.00589	CcSEcCtD
Methylnaltrexone—Gastrointestinal pain—Estropipate—osteoporosis	0.00588	0.00588	CcSEcCtD
Methylnaltrexone—Oedema—Ethinyl Estradiol—osteoporosis	0.00582	0.00583	CcSEcCtD
Methylnaltrexone—Erythema—Conjugated Estrogens—osteoporosis	0.00582	0.00583	CcSEcCtD
Methylnaltrexone—Gastrointestinal pain—Alendronate—osteoporosis	0.00579	0.0058	CcSEcCtD
Methylnaltrexone—Pain—Calcitriol—osteoporosis	0.00577	0.00578	CcSEcCtD
Methylnaltrexone—Flatulence—Conjugated Estrogens—osteoporosis	0.00573	0.00574	CcSEcCtD
Methylnaltrexone—Nervous system disorder—Ethinyl Estradiol—osteoporosis	0.00571	0.00572	CcSEcCtD
Methylnaltrexone—Gastrointestinal pain—Raloxifene—osteoporosis	0.00569	0.0057	CcSEcCtD
Methylnaltrexone—Diarrhoea—Etidronic acid—osteoporosis	0.00568	0.00569	CcSEcCtD
Methylnaltrexone—Abdominal pain—Estropipate—osteoporosis	0.00568	0.00569	CcSEcCtD
Methylnaltrexone—Skin disorder—Ethinyl Estradiol—osteoporosis	0.00566	0.00567	CcSEcCtD
Methylnaltrexone—Gastrointestinal pain—Ibandronate—osteoporosis	0.00563	0.00564	CcSEcCtD
Methylnaltrexone—Abdominal pain—Alendronate—osteoporosis	0.00559	0.0056	CcSEcCtD
Methylnaltrexone—Nervous system disorder—Risedronate—osteoporosis	0.00557	0.00558	CcSEcCtD
Methylnaltrexone—Skin disorder—Risedronate—osteoporosis	0.00552	0.00552	CcSEcCtD
Methylnaltrexone—Gastrointestinal pain—Calcitriol—osteoporosis	0.00552	0.00552	CcSEcCtD
Methylnaltrexone—Abdominal pain—Raloxifene—osteoporosis	0.0055	0.00551	CcSEcCtD
Methylnaltrexone—Abdominal pain—Ibandronate—osteoporosis	0.00545	0.00546	CcSEcCtD
Methylnaltrexone—Oedema—Pamidronate—osteoporosis	0.0054	0.00541	CcSEcCtD
Methylnaltrexone—Abdominal pain—Calcitriol—osteoporosis	0.00533	0.00534	CcSEcCtD
Methylnaltrexone—Nervous system disorder—Pamidronate—osteoporosis	0.00529	0.0053	CcSEcCtD
Methylnaltrexone—Vomiting—Etidronic acid—osteoporosis	0.00528	0.00529	CcSEcCtD
Methylnaltrexone—Hyperhidrosis—Pamidronate—osteoporosis	0.00522	0.00523	CcSEcCtD
Methylnaltrexone—Unspecified disorder of skin and subcutaneous tissue—Zoledronate—osteoporosis	0.00511	0.00512	CcSEcCtD
Methylnaltrexone—Gastrointestinal disorder—Ethinyl Estradiol—osteoporosis	0.00503	0.00504	CcSEcCtD
Methylnaltrexone—Nausea—Etidronic acid—osteoporosis	0.00493	0.00494	CcSEcCtD
Methylnaltrexone—Oedema—Zoledronate—osteoporosis	0.00493	0.00494	CcSEcCtD
Methylnaltrexone—Unspecified disorder of skin and subcutaneous tissue—Conjugated Estrogens—osteoporosis	0.00492	0.00493	CcSEcCtD
Methylnaltrexone—Diarrhoea—Estropipate—osteoporosis	0.00492	0.00492	CcSEcCtD
Methylnaltrexone—Gastrointestinal disorder—Risedronate—osteoporosis	0.0049	0.00491	CcSEcCtD
Methylnaltrexone—Pain—Risedronate—osteoporosis	0.00486	0.00486	CcSEcCtD
Methylnaltrexone—Diarrhoea—Alendronate—osteoporosis	0.00484	0.00485	CcSEcCtD
Methylnaltrexone—Nervous system disorder—Zoledronate—osteoporosis	0.00484	0.00484	CcSEcCtD
Methylnaltrexone—Skin disorder—Zoledronate—osteoporosis	0.00479	0.0048	CcSEcCtD
Methylnaltrexone—Hyperhidrosis—Zoledronate—osteoporosis	0.00477	0.00477	CcSEcCtD
Methylnaltrexone—Gastrointestinal pain—Ethinyl Estradiol—osteoporosis	0.00476	0.00477	CcSEcCtD
Methylnaltrexone—Diarrhoea—Raloxifene—osteoporosis	0.00476	0.00477	CcSEcCtD
Methylnaltrexone—Dizziness—Estropipate—osteoporosis	0.00475	0.00476	CcSEcCtD
Methylnaltrexone—Oedema—Conjugated Estrogens—osteoporosis	0.00475	0.00476	CcSEcCtD
Methylnaltrexone—Diarrhoea—Ibandronate—osteoporosis	0.00471	0.00472	CcSEcCtD
Methylnaltrexone—Dizziness—Alendronate—osteoporosis	0.00468	0.00469	CcSEcCtD
Methylnaltrexone—Gastrointestinal disorder—Pamidronate—osteoporosis	0.00466	0.00467	CcSEcCtD
Methylnaltrexone—Nervous system disorder—Conjugated Estrogens—osteoporosis	0.00466	0.00466	CcSEcCtD
Methylnaltrexone—Erythema—Estradiol—osteoporosis	0.00466	0.00466	CcSEcCtD
Methylnaltrexone—Gastrointestinal pain—Risedronate—osteoporosis	0.00464	0.00465	CcSEcCtD
Methylnaltrexone—Pain—Pamidronate—osteoporosis	0.00462	0.00462	CcSEcCtD
Methylnaltrexone—Diarrhoea—Calcitriol—osteoporosis	0.00461	0.00462	CcSEcCtD
Methylnaltrexone—Skin disorder—Conjugated Estrogens—osteoporosis	0.00461	0.00462	CcSEcCtD
Methylnaltrexone—Abdominal pain—Ethinyl Estradiol—osteoporosis	0.0046	0.00461	CcSEcCtD
Methylnaltrexone—Dizziness—Raloxifene—osteoporosis	0.0046	0.00461	CcSEcCtD
Methylnaltrexone—Hyperhidrosis—Conjugated Estrogens—osteoporosis	0.00459	0.0046	CcSEcCtD
Methylnaltrexone—Flatulence—Estradiol—osteoporosis	0.00459	0.00459	CcSEcCtD
Methylnaltrexone—Vomiting—Estropipate—osteoporosis	0.00457	0.00458	CcSEcCtD
Methylnaltrexone—Dizziness—Ibandronate—osteoporosis	0.00456	0.00456	CcSEcCtD
Methylnaltrexone—Vomiting—Alendronate—osteoporosis	0.0045	0.00451	CcSEcCtD
Methylnaltrexone—Abdominal pain—Risedronate—osteoporosis	0.00449	0.0045	CcSEcCtD
Methylnaltrexone—Vomiting—Raloxifene—osteoporosis	0.00443	0.00443	CcSEcCtD
Methylnaltrexone—Gastrointestinal pain—Pamidronate—osteoporosis	0.00441	0.00442	CcSEcCtD
Methylnaltrexone—Vomiting—Ibandronate—osteoporosis	0.00438	0.00439	CcSEcCtD
Methylnaltrexone—Vomiting—Calcitriol—osteoporosis	0.00429	0.0043	CcSEcCtD
Methylnaltrexone—Nausea—Estropipate—osteoporosis	0.00427	0.00427	CcSEcCtD
Methylnaltrexone—Abdominal pain—Pamidronate—osteoporosis	0.00427	0.00427	CcSEcCtD
Methylnaltrexone—Gastrointestinal disorder—Zoledronate—osteoporosis	0.00426	0.00426	CcSEcCtD
Methylnaltrexone—Pain—Zoledronate—osteoporosis	0.00422	0.00422	CcSEcCtD
Methylnaltrexone—Nausea—Alendronate—osteoporosis	0.0042	0.00421	CcSEcCtD
Methylnaltrexone—Nausea—Raloxifene—osteoporosis	0.00413	0.00414	CcSEcCtD
Methylnaltrexone—Gastrointestinal disorder—Conjugated Estrogens—osteoporosis	0.0041	0.00411	CcSEcCtD
Methylnaltrexone—Nausea—Ibandronate—osteoporosis	0.00409	0.0041	CcSEcCtD
Methylnaltrexone—Pain—Conjugated Estrogens—osteoporosis	0.00406	0.00407	CcSEcCtD
Methylnaltrexone—Gastrointestinal pain—Zoledronate—osteoporosis	0.00403	0.00404	CcSEcCtD
Methylnaltrexone—Nausea—Calcitriol—osteoporosis	0.00401	0.00401	CcSEcCtD
Methylnaltrexone—Diarrhoea—Ethinyl Estradiol—osteoporosis	0.00398	0.00399	CcSEcCtD
Methylnaltrexone—Unspecified disorder of skin and subcutaneous tissue—Estradiol—osteoporosis	0.00394	0.00394	CcSEcCtD
Methylnaltrexone—Abdominal pain—Zoledronate—osteoporosis	0.0039	0.0039	CcSEcCtD
Methylnaltrexone—Diarrhoea—Risedronate—osteoporosis	0.00389	0.00389	CcSEcCtD
Methylnaltrexone—Gastrointestinal pain—Conjugated Estrogens—osteoporosis	0.00388	0.00389	CcSEcCtD
Methylnaltrexone—Dizziness—Ethinyl Estradiol—osteoporosis	0.00385	0.00386	CcSEcCtD
Methylnaltrexone—Oedema—Estradiol—osteoporosis	0.0038	0.00381	CcSEcCtD
Methylnaltrexone—Dizziness—Risedronate—osteoporosis	0.00375	0.00376	CcSEcCtD
Methylnaltrexone—Abdominal pain—Conjugated Estrogens—osteoporosis	0.00375	0.00376	CcSEcCtD
Methylnaltrexone—Nervous system disorder—Estradiol—osteoporosis	0.00373	0.00373	CcSEcCtD
Methylnaltrexone—Vomiting—Ethinyl Estradiol—osteoporosis	0.0037	0.00371	CcSEcCtD
Methylnaltrexone—Diarrhoea—Pamidronate—osteoporosis	0.00369	0.0037	CcSEcCtD
Methylnaltrexone—Skin disorder—Estradiol—osteoporosis	0.00369	0.0037	CcSEcCtD
Methylnaltrexone—Hyperhidrosis—Estradiol—osteoporosis	0.00367	0.00368	CcSEcCtD
Methylnaltrexone—Vomiting—Risedronate—osteoporosis	0.00361	0.00362	CcSEcCtD
Methylnaltrexone—Dizziness—Pamidronate—osteoporosis	0.00357	0.00358	CcSEcCtD
Methylnaltrexone—Nausea—Ethinyl Estradiol—osteoporosis	0.00346	0.00346	CcSEcCtD
Methylnaltrexone—Vomiting—Pamidronate—osteoporosis	0.00343	0.00344	CcSEcCtD
Methylnaltrexone—Diarrhoea—Zoledronate—osteoporosis	0.00337	0.00338	CcSEcCtD
Methylnaltrexone—Nausea—Risedronate—osteoporosis	0.00337	0.00338	CcSEcCtD
Methylnaltrexone—Gastrointestinal disorder—Estradiol—osteoporosis	0.00328	0.00329	CcSEcCtD
Methylnaltrexone—Dizziness—Zoledronate—osteoporosis	0.00326	0.00327	CcSEcCtD
Methylnaltrexone—Pain—Estradiol—osteoporosis	0.00325	0.00325	CcSEcCtD
Methylnaltrexone—Diarrhoea—Conjugated Estrogens—osteoporosis	0.00325	0.00325	CcSEcCtD
Methylnaltrexone—Nausea—Pamidronate—osteoporosis	0.00321	0.00321	CcSEcCtD
Methylnaltrexone—Dizziness—Conjugated Estrogens—osteoporosis	0.00314	0.00314	CcSEcCtD
Methylnaltrexone—Vomiting—Zoledronate—osteoporosis	0.00313	0.00314	CcSEcCtD
Methylnaltrexone—Gastrointestinal pain—Estradiol—osteoporosis	0.00311	0.00311	CcSEcCtD
Methylnaltrexone—Vomiting—Conjugated Estrogens—osteoporosis	0.00302	0.00302	CcSEcCtD
Methylnaltrexone—Abdominal pain—Estradiol—osteoporosis	0.003	0.00301	CcSEcCtD
Methylnaltrexone—Nausea—Zoledronate—osteoporosis	0.00293	0.00293	CcSEcCtD
Methylnaltrexone—Nausea—Conjugated Estrogens—osteoporosis	0.00282	0.00282	CcSEcCtD
Methylnaltrexone—Diarrhoea—Estradiol—osteoporosis	0.0026	0.0026	CcSEcCtD
Methylnaltrexone—Dizziness—Estradiol—osteoporosis	0.00251	0.00252	CcSEcCtD
Methylnaltrexone—Vomiting—Estradiol—osteoporosis	0.00242	0.00242	CcSEcCtD
Methylnaltrexone—Nausea—Estradiol—osteoporosis	0.00226	0.00226	CcSEcCtD
Methylnaltrexone—Naloxone—ESR1—osteoporosis	0.00155	1	CrCbGaD
